Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn's disease: Results from imagine 1 and imagine 2

Frank M. Ruemmele, Joel Rosh, William A. Faubion, Marla C. Dubinsky, Dan Turner, Andreas Lazar, Samantha Eichner, Jen Fue Maa, Gabriela Alperovich, Anne M. Robinson, Jeffrey S. Hyams

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Background and Aims: Adalimumab has been shown to be more effective than placebo in healing fistulae in adults with moderately to severely active Crohn's disease. The efficacy and safety of adalimumab in healing fistulae in children/adolescents with Crohn's disease from the 52-week IMAgINE 1 clinical trial, and its open-label extension IMAgINE 2, are reported. Methods: Children/adolescents with perianal fistulae at baseline of IMAgINE 1 were assessed for fistula closure and improvement during IMAgINE 1 [Weeks 0-52] and from Week 0 of IMAgINE 2 [Week 52 of IMAgINE 1] through to Week 240 of IMAgINE 2 using non-responder imputation. Results: A total of 36 children/adolescents had fistulae at baseline of IMAgINE 1 and were included in the analysis. Fistula closure and improvement were observed in 44.4% and 52.8%, respectively, at Week 12. Rates of closure and improvement were maintained throughout the analysis period to Week 292. No new safety signals were identified. Conclusions: In children/adolescents with moderately to severely active, fistulizing Crohn's disease, adalimumab induced perianal fistula closure and improvement within 12 weeks of treatment, with rates that were sustained for more than 5 years.The safety profile of adalimumab in patients with fistulae at baseline was similar to that of the overall population in IMAgINE 1/2. ClinicalTrials.gov identifiers: IMAgINE 1 (NCT00409682); IMAgINE 2 (NCT00686374).

Original languageEnglish (US)
Pages (from-to)1249-1254
Number of pages6
JournalJournal of Crohn's and Colitis
Volume12
Issue number10
DOIs
StatePublished - 2018

Keywords

  • Adalimumab
  • Anti-TNF
  • Fistula

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn's disease: Results from imagine 1 and imagine 2'. Together they form a unique fingerprint.

  • Cite this

    Ruemmele, F. M., Rosh, J., Faubion, W. A., Dubinsky, M. C., Turner, D., Lazar, A., Eichner, S., Maa, J. F., Alperovich, G., Robinson, A. M., & Hyams, J. S. (2018). Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active Crohn's disease: Results from imagine 1 and imagine 2. Journal of Crohn's and Colitis, 12(10), 1249-1254. https://doi.org/10.1093/ecco-jcc/jjy087